Takahiro Matsuya
Kanazawa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takahiro Matsuya.
Biological Psychiatry | 2007
Kenji Takahashi; Taku Nagai; Hiroyuki Kamei; Kenji Maeda; Takahiro Matsuya; Sawako Arai; Hiroyuki Mizoguchi; Yukio Yoneda; Toshitaka Nabeshima; Kazuhiro Takuma; Kiyofumi Yamada
BACKGROUND Prepulse inhibition (PPI) of the startle response is a measure of the inhibitory function and time-linked information processing by which a weak sensory stimulus (the prepulse) inhibits the startle response caused by a sudden intense stimulus. We attempted to clarify the neuronal circuits underlying the control of PPI of the startle reflex in mice. METHODS c-Fos immunohistochemistry was used to detect neurons activated by startle pulse and/or prepulse trials. Behavioural pharmacology and tracing studies were also conducted. RESULTS The lateral globus pallidus (LGP) was activated by prepulses. Activation of the caudal pontine reticular nucleus (PnC) evoked by the startle pulses was inhibited under PPI conditions. Double-immunostaining revealed that c-Fos-positive cells in the LGP following prepulse trials were GABAergic neurons. Bilateral microinjections of lidocaine into the LGP resulted in an impairment of PPI. Fluoro-gold infusion into the PnC and the pedunculopontine tegmental nucleus (PPTg) retrogradely labeled neurons in the PPTg and LGP, respectively. Microinjections of phaclofen into the PPTg significantly impaired PPI. CONCLUSIONS These results suggest that GABAergic neurons in the LGP which project to the PPTg play a crucial role through the activation of GABAB receptors in the regulation of PPI of the startle reflex in mice.
The Journal of Nuclear Medicine | 2008
Takuma Mihara; Akihiro Noda; Hiroshi Arai; Kayoko Mihara; Akinori Iwashita; Yoshihiro Murakami; Takahiro Matsuya; Sosuke Miyoshi; Shintaro Nishimura; Nobuya Matsuoka
The purpose of the present study was to measure adenosine A2A receptor (A2AR) occupancy in the brain by a novel adenosine A1/A2A antagonist, 5-[5-amino-3-(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), and to determine the degree of receptor occupancy necessary to inhibit haloperidol-induced catalepsy in rhesus monkeys. Methods: A2AR occupancy by ASP5854 (0.001–0.1 mg/kg) was examined in the striatum using an A2AR-specific radiotracer, 11C-SCH442416, and PET in conscious rhesus monkeys. A2AR occupancy was monitored after a single intravenous administration of ASP5854 in 3 animals, and a dynamic PET scan was performed at 1, 4, and 8 h after an intravenous bolus injection of the tracer for approximately 740 MBq. Catalepsy was induced by haloperidol (0.03 mg/kg, intramuscularly) and examined for incidence and duration. Results: ASP5854 dose-dependently increased A2AR occupancy in the striatum and showed long-lasting occupancy even after the reduction of plasma concentration. Haloperidol induced severe catalepsy at 40 min after intramuscular injection. The incidence and duration of cataleptic posture were dose-dependently reduced by ASP5854 at 1 h after oral administration, and the minimum ED50 value was 0.1 mg/kg. Administration of a dose of 0.1 mg/kg yielded a plasma concentration of 97 ± 16.3 ng/mL, which corresponded to 85%–90% of A2AR occupancy. Conclusion: These results showed that ASP5854 antagonized A2AR in the striatum, and the dissociation from A2AR was relatively slow. In addition, more than 85% A2AR occupancy by ASP5854 resulted in an inhibition of haloperidol-induced catalepsy. Thus, such a pharmacodynamic study directly demonstrates both the kinetics of a drug in the brain and the relationship between dose-dependent receptor occupancy and plasma level.
Journal of Pharmacological Sciences | 2007
Takahiro Matsuya; Kazuhiro Takuma; Kosuke Sato; Makoto Asai; Yoshihiro Murakami; Sosuke Miyoshi; Akihiro Noda; Taku Nagai; Hiroyuki Mizoguchi; Shintaro Nishimura; Kiyofumi Yamada
Neuroreport | 2006
Taku Nagai; Hiroyuki Kamei; Misato Dohniwa; Masanori Takayanagi; Masakazu Suzuki; Takahiro Matsuya; Toshitaka Nabeshima; Kazuhiro Takuma; Kiyofumi Yamada
European Journal of Nuclear Medicine and Molecular Imaging | 2006
Yusuke Nomura; Ichiro Matsunari; Hiroyuki Takamatsu; Yoshihiro Murakami; Takahiro Matsuya; Junichi Taki; Kenichi Nakajima; Stephan G. Nekolla; Wei-Ping Chen; Kouji Kajinami
Journal of Labelled Compounds and Radiopharmaceuticals | 2005
Takahiro Matsuya; Hiroyuki Takamatsu; Yoshihiro Murakami; Akihiro Noda; Kazuhiko Osoda; Rikiya Ichise; Yuji Awaga; Shintaro Nishimura
Society of Nuclear Medicine Annual Meeting Abstracts | 2007
Yoshihiro Murakami; Akihiro Noda; Kazuhiko Osoda; Takahiro Matsuya; Hajime Sogabe; Kazuhiko Take; Nobuya Matsuoka; Shintaro Nishimura
Archive | 2013
Yoshihiro Murakami; Takahiro Matsuya; Aya Kita; Kentaro Yamanaka; Akihiro Noda; Keisuke Mitsuoka; Takahito Nakahara; Sosuke Miyoshi; Shintaro Nishimura
Society of Nuclear Medicine Annual Meeting Abstracts | 2007
Akihiro Noda; Yoshihiro Murakami; Takahiro Matsuya; Sosuke Miyoshi; Takuma Mihara; Nobuya Matsuoka; Shintaro Nishimura
Archive | 2006
Katsuya Harada; Takahiro Matsuya; Takayuki Yamaji; Yoshihiro Murakami; Akihiro Noda; Hiroyuki Takamatsu; Kazuhiko Osoda; Nobuya Matsuoka; Shintaro Nishimura